Archives

The Sydney Memory and Ageing Study (Sydney MAS) began in 2005 to examine the clinical characteristics and prevalence of mild cognitive impairment (MCI) and related syndromes, and to determine the rate of change in cognitive function over time.

Non-demented community-dwelling individuals (N=1037) aged 70-90 were recruited from two areas of Sydney, following a random approach to 8,914 individuals on the electoral roll. They underwent detailed neuropsychiatric and medical assessments and donated a blood sample for clinical chemistry, proteomics and genomics. A knowledgeable informant was also interviewed. Structural MRI scans were performed on 554 individuals, and subgroups participated in studies of falls and balance, metabolic and inflammatory markers, functional MRI and prospective memory. The cohort is to be followed up with brief telephone reviews annually, and detailed assessments biannually.

Last update – 20/07/2017

The Three-City Study (3C Study) is a population-based longitudinal study of the relation between vascular diseases and dementia in persons aged 65 years and older. A total of 9,294 participants (3,649 men and 5,645 women) were recruited from three French cities: Bordeaux (2,104), Dijon (4,931) and Montpellier (2,259).

The principal objective is to estimate the risk of dementia (Alzheimer’s disease and other types) that may be attributed to vascular factors.

In follow up 1 and 2 (2001-2004) participants were interviewed and subjected to physical and cognitive testing. In follow up 3 (2005-2012) participants completed a postal questionnaire. The third, fourth, and fith waves of follow-up examinations started in 2006 and finished in 2012. A sixth follow-up is ongoing.

Last update – 03/02/2017

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on ADNI-info.org. All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

Last update – 07/02/2017

Aims & objective

To find out the known as well as some new factors which increase the risk of occurrence of stroke (half body paralysis, Lakwa) and of memory problem and other brain related problems.
To identify a group of apparently healthy people (50 years and above), carry out their health check up and follow them up over several years to detect any health problems (like heart attack, lakwa, memory problems) with increasing age.
To investigate the prevalence and incidence of and risk factors for stroke and cognitive decline in the elderly.

Updates about the health of the participants will be obtained from telephone follow-ups every six months and physical check-ups every three years. The study is expected to last for at least 10 years.

Last update – 02/02/2017

The AMPLE study has been set up to investigate differences and outcomes in those with Lewy body dementia with and without concurrent Alzheimer’s disease/pathology. The principle aim of AMPLE is to undertake amyloid PET imaging in Lewy Body Dementia (LBD) and Alzheimer’s disease (AD) of 80 participants over the age of 60 and investigate the distribution of amyloid burden in LBD relative to AD and controls at baseline. A further aim is to determine the relationship between amyloid levels at baseline, clinical features of the disease, other imaging changes and subsequent clinical course in follow up.

Primary analysis would divide LBD patients into high and low amyloid burden with participants then compared on clinical features with AD-like symptoms and cognitive profiles. Follow up will be completed annually through surveys and clinical examinations.

Last update – 01/02/2017

The Dunedin Multidisciplinary Health and Development Study (DMHDS) is an ongoing, longitudinal study of the health, development and well-being of a general sample of New Zealanders. They were studied at birth (1972-73), followed up and assessed at the age of three when the longitudinal study was established. Since then they have been assessed every two years until the age of 15, then at ages 18 (1990-91), 21 (1993-94), 26 (1998-99), 32 (2003-2005), and 38 (2010-2012). It is planned to next see the Study members at age 44/45 and beyond.

Last update – 31/01/2017

GENFI is a five year longitudinal biomarker cohort study of genetic Frontotemporal Dementia and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with the disorder as well as at-risk members of families). Non-carrier first-degree relatives will serve as a control group.
All GENFI participants will be assessed longitudinally (annually) with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols.

Last update – 25/01/2017

The HCS is a population-based cohort study established to assess factors important in the health, well-being, social functioning and economic consequences of ageing. The participants included community-dwelling men and women aged 55-85 years of age who reside in Newcastle, New South Wales (NSW), Australia. They were randomly selected from the NSW State electoral roll and contacted between December 2004 and December 2007.

The participants’ study data was collected through self-report postal questionnaires which covered a wide range of variables but also linked with local and national health information databases and hospital records. These provided follow-up on use of prescription medication, health service utilization and hospitalizations, morbidity and mortality. There was also a baseline clinic visit which measured a wide variety of parameters including hearing, vision, smell, balance, cognition, and lung function. Medications and diagnoses have been collected not only at baseline but also at periodic intervals during follow-up.

Last update – 31/01/2017

The main objective of the Longitudinal Ageing Study in India (LASI) is to provide comprehensive longitudinal evidence base on health, social and economic wellbeing of elderly population in India.

LASI main wave’s covers 30 states and 6 union territories of India covering a panel sample size of 60,250 elderly persons aged 45 years and above. The long-term goal of LASI is to continue this survey for the next 25 years with the first wave planned in the year 2016-17 and second wave in 2018-19. LASI aims to obtain all the indicators for each of the 30 states and 6 union territories. In addition, LASI aims at obtaining indicators for each of the four metropolitan cities of Delhi, Kolkata, Mumbai and Chennai.

Last update – 10/02/2017

The first wave of the MIDUS study collected survey data from a total of 7,108 participants. The baseline sample was comprised of individuals from four subsamples:

a national RDD (random digit dialing) sample (n=3,487);
oversamples from five metropolitan areas in the U.S. (n=757)
siblings of individuals from the RDD sample (n=950); and (4) a national RDD sample of twin pairs (n=1,914).

All eligible participants were non-institutionalized, English-speaking adults in the coterminous United States, aged 25 to 74. Data from the above samples were collected primarily in 1995/96.

Last update – 03/02/2017